{ "cells": [ { "cell_type": "code", "execution_count": 1, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n", " from tqdm.autonotebook import tqdm, trange\n" ] } ], "source": [ "from sentence_transformers import SentenceTransformer, util\n", "import pandas as pd\n", "import re" ] }, { "cell_type": "code", "execution_count": 14, "metadata": {}, "outputs": [], "source": [ "# Target列を分割する関数\n", "def split_target(target):\n", " # 指定された区切り文字で分割\n", " split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n", " # 空白文字を除外してリストとして返す\n", " return [word.strip() for word in split_words if word.strip()]\n", "\n", "\n", "# Target列を分割する関数（改良後）\n", "def split_target_English(target):\n", " # 区切り文字を (,) or (\\n) or (、) or (・) または文字列\"or\" として扱う\n", " # 正規表現では、パイプ(|)でor条件を定義し、\"(?: ... )\"はグルーピングのみ行う非捕捉グループ\n", " # [,\\n、・] はいずれかの1文字とマッチ\n", " # or は文字列全体とマッチ\n", " # 複数連続した区切り文字をまとめて1回の分割として扱うために+(1回以上)とする\n", " split_words = re.split(r'(?:[,\\n、・]|or)+', target)\n", " \n", " # 空白文字を除外してリストとして返す\n", " return [word.strip() for word in split_words if word.strip()]" ] }, { "cell_type": "code", "execution_count": 15, "metadata": {}, "outputs": [], "source": [ "basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241215Cancer.csv', index_col=0)\n", "basedf = basedf.dropna(subset=['試験等のフェーズ'])\n", "# Target列を分割してTargetWord列を追加\n", "basedf['TargetWord'] = basedf['TargetEnglish'].apply(split_target_English)" ] }, { "cell_type": "code", "execution_count": 16, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTargetJTargetTargetEnglish研究・治験の目的試験等のフェーズ試験の種類...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
0jRCT2031240552NCT06599502NaNKRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併...以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌Non-Small Cell Lung Cancer (NSCLC) Pancreatic ...Treatment1-2NaN...treatment purpose1. Participant must be 18 years or more, or th...1. Any significant laboratory finding or any s...18age old overNo limitBothNaNNaNAZD0022[Non-Small Cell Lung Cancer (NSCLC) Pancreatic...
3jRCT2031240547NaNNaNFGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu...切除不能進行・再発の胃または食道胃接合部腺癌切除不能進行・再発の胃または食道胃接合部腺癌Advanced Gastric or Gastroesophageal Junction ...フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又...2NaN...treatment purpose1) Histologically documented gastric or GEJ ad...1) Prior treatment with taxanes 2) Prior treat...18age old overNo limitBothNaNNaN- Bemarituzumab (15mg/kg, intravenous, Day1, 1...[Advanced Gastric, Gastroesophageal Junction C...
5jRCT2031240542NaNNaN自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド...多発性骨髄腫多発性骨髄腫Multiple Myeloma自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ...3NaN...treatment purpose1. Is at least 18 or the legal age of consent ...Participants are excluded from the study if an...18age old overNo limitBothNaNNaNArm A: Belantamab Mafodotin is intraveniously ...[Multiple Myeloma]
7jRCT2031240536NCT06003231NaN既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita...頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌Head and neck squamous cell carcinoma/Non-smal...既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形...2NaN...treatment purposeCohort 1: Head and neck squamous cell carcinom...- Prior treatment with a monomethyl auristatin...18age old overNo limitBothNaNNaNExperimental Arm - Disitamab vedotin 1.5 mg/kg...[Head and neck squamous cell carcinoma/Non-sma...
9jRCT2031240530NaNNaNHER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra...HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...Stage II-III HER2-Amplified or HER2-Mutant Non...HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...2NaN...treatment purpose1. Signed informed consent form 2. Age >= 18 y...1. NSCLC that is clinically T4 by virtue of me...18age old overNo limitBothNaNNaNThe study drug will be administered as an IV i...[Stage II-III HER2-Amplified, HER2-Mutant Non-...
..................................................................
729jRCT2031200057NaNNaN治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験乳がん乳がんBreast cancerTDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...1NaN...treatment purpose<Disease Characteristics> 1)Patients with inop...1)Patients correspond to either of the followi...20age old overNo limitFemaleNaNBreast cancerFor the target tumor, the dose settled at each...[Breast cancer]
739jRCT2073200004NaNNaN切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験膵癌膵癌Pancreatic cancer切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。1-2NaN...treatment purposeThe patients with pancreatic tumors must meet ...1) Patients with the following complications: ...20age old overNo limitBothNaNPancreatic ductal carcinoma, unresectableIntratumoral administration of oncolytic virus[Pancreatic cancer]
760jRCT2033190086NaNNaN悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...悪性黒色腫悪性黒色腫malignant melanoma第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...1-2NaN...treatment purpose(Phase 1) 1) Histologically confirmed malignan...(Phase 1 and 2) 1) Patients who have brain and...20age old overNo limitBothNaNmalignamt melanoma, advanced stageTest drug (T-hIL12) will be administered into ...[malignant melanoma]
762jRCT2031190072NaNNaN切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験肝細胞癌肝細胞癌Hepatocellular carcinoma切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験1NaN...treatment purpose1) Histologically or cytologically confirmed h...1) CNS metastases that are symptomatic or requ...20age 0month 0week old overNo limitBothNaNCancer peptide vaccineReconstitute two kinds of cancer peptide vacci...[Hepatocellular carcinoma]
772jRCT2051190009NCT03818893JapicCTI-194618進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...進行性悪性黒色腫進行性悪性黒色腫advanced melanoma抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...1-2NaN...treatment purposeInclusion criteria Patients meeting all of the...Exclusion criteria Patients meeting any of the...20age old over86age old notBothNaNadvanced melanomacombination therapy of intracutaneous GEN0101 ...[advanced melanoma]
\n", "

427 rows × 40 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "0 jRCT2031240552 NCT06599502 NaN \n", "3 jRCT2031240547 NaN NaN \n", "5 jRCT2031240542 NaN NaN \n", "7 jRCT2031240536 NCT06003231 NaN \n", "9 jRCT2031240530 NaN NaN \n", ".. ... ... ... \n", "729 jRCT2031200057 NaN NaN \n", "739 jRCT2073200004 NaN NaN \n", "760 jRCT2033190086 NaN NaN \n", "762 jRCT2031190072 NaN NaN \n", "772 jRCT2051190009 NCT03818893 JapicCTI-194618 \n", "\n", " Title \\\n", "0 KRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併... \n", "3 FGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu... \n", "5 自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド... \n", "7 既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita... \n", "9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra... \n", ".. ... \n", "729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 \n", "739 切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験 \n", "760 悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第... \n", "762 切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験 \n", "772 進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体... \n", "\n", " TargetJ \\\n", "0 以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌 \n", "3 切除不能進行・再発の胃または食道胃接合部腺癌 \n", "5 多発性骨髄腫 \n", "7 頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌 \n", "9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... \n", ".. ... \n", "729 乳がん \n", "739 膵癌 \n", "760 悪性黒色腫 \n", "762 肝細胞癌 \n", "772 進行性悪性黒色腫 \n", "\n", " Target \\\n", "0 以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌 \n", "3 切除不能進行・再発の胃または食道胃接合部腺癌 \n", "5 多発性骨髄腫 \n", "7 頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌 \n", "9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... \n", ".. ... \n", "729 乳がん \n", "739 膵癌 \n", "760 悪性黒色腫 \n", "762 肝細胞癌 \n", "772 進行性悪性黒色腫 \n", "\n", " TargetEnglish \\\n", "0 Non-Small Cell Lung Cancer (NSCLC) Pancreatic ... \n", "3 Advanced Gastric or Gastroesophageal Junction ... \n", "5 Multiple Myeloma \n", "7 Head and neck squamous cell carcinoma/Non-smal... \n", "9 Stage II-III HER2-Amplified or HER2-Mutant Non... \n", ".. ... \n", "729 Breast cancer \n", "739 Pancreatic cancer \n", "760 malignant melanoma \n", "762 Hepatocellular carcinoma \n", "772 advanced melanoma \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n", "0 Treatment 1-2 NaN ... \n", "3 フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又... 2 NaN ... \n", "5 自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ... 3 NaN ... \n", "7 既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形... 2 NaN ... \n", "9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... 2 NaN ... \n", ".. ... ... ... ... \n", "729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n", "739 切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。 1-2 NaN ... \n", "760 第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ... 1-2 NaN ... \n", "762 切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験 1 NaN ... \n", "772 抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010... 1-2 NaN ... \n", "\n", " purpose Inclusion Criteria \\\n", "0 treatment purpose 1. Participant must be 18 years or more, or th... \n", "3 treatment purpose 1) Histologically documented gastric or GEJ ad... \n", "5 treatment purpose 1. Is at least 18 or the legal age of consent ... \n", "7 treatment purpose Cohort 1: Head and neck squamous cell carcinom... \n", "9 treatment purpose 1. Signed informed consent form 2. Age >= 18 y... \n", ".. ... ... \n", "729 treatment purpose 1)Patients with inop... \n", "739 treatment purpose The patients with pancreatic tumors must meet ... \n", "760 treatment purpose (Phase 1) 1) Histologically confirmed malignan... \n", "762 treatment purpose 1) Histologically or cytologically confirmed h... \n", "772 treatment purpose Inclusion criteria Patients meeting all of the... \n", "\n", " Exclusion Criteria \\\n", "0 1. Any significant laboratory finding or any s... \n", "3 1) Prior treatment with taxanes 2) Prior treat... \n", "5 Participants are excluded from the study if an... \n", "7 - Prior treatment with a monomethyl auristatin... \n", "9 1. NSCLC that is clinically T4 by virtue of me... \n", ".. ... \n", "729 1)Patients correspond to either of the followi... \n", "739 1) Patients with the following complications: ... \n", "760 (Phase 1 and 2) 1) Patients who have brain and... \n", "762 1) CNS metastases that are symptomatic or requ... \n", "772 Exclusion criteria Patients meeting any of the... \n", "\n", " Age Minimum Age Maximum Gender \\\n", "0 18age old over No limit Both \n", "3 18age old over No limit Both \n", "5 18age old over No limit Both \n", "7 18age old over No limit Both \n", "9 18age old over No limit Both \n", ".. ... ... ... \n", "729 20age old over No limit Female \n", "739 20age old over No limit Both \n", "760 20age old over No limit Both \n", "762 20age 0month 0week old over No limit Both \n", "772 20age old over 86age old not Both \n", "\n", " Discontinuation Criteria Keyword \\\n", "0 NaN NaN \n", "3 NaN NaN \n", "5 NaN NaN \n", "7 NaN NaN \n", "9 NaN NaN \n", ".. ... ... \n", "729 NaN Breast cancer \n", "739 NaN Pancreatic ductal carcinoma, unresectable \n", "760 NaN malignamt melanoma, advanced stage \n", "762 NaN Cancer peptide vaccine \n", "772 NaN advanced melanoma \n", "\n", " Intervention(s) \\\n", "0 AZD0022 \n", "3 - Bemarituzumab (15mg/kg, intravenous, Day1, 1... \n", "5 Arm A: Belantamab Mafodotin is intraveniously ... \n", "7 Experimental Arm - Disitamab vedotin 1.5 mg/kg... \n", "9 The study drug will be administered as an IV i... \n", ".. ... \n", "729 For the target tumor, the dose settled at each... \n", "739 Intratumoral administration of oncolytic virus \n", "760 Test drug (T-hIL12) will be administered into ... \n", "762 Reconstitute two kinds of cancer peptide vacci... \n", "772 combination therapy of intracutaneous GEN0101 ... \n", "\n", " TargetWord \n", "0 [Non-Small Cell Lung Cancer (NSCLC) Pancreatic... \n", "3 [Advanced Gastric, Gastroesophageal Junction C... \n", "5 [Multiple Myeloma] \n", "7 [Head and neck squamous cell carcinoma/Non-sma... \n", "9 [Stage II-III HER2-Amplified, HER2-Mutant Non-... \n", ".. ... \n", "729 [Breast cancer] \n", "739 [Pancreatic cancer] \n", "760 [malignant melanoma] \n", "762 [Hepatocellular carcinoma] \n", "772 [advanced melanoma] \n", "\n", "[427 rows x 40 columns]" ] }, "execution_count": 16, "metadata": {}, "output_type": "execute_result" } ], "source": [ "basedf.dropna(subset=['TargetEnglish'])" ] }, { "cell_type": "code", "execution_count": 17, "metadata": {}, "outputs": [ { "data": { "application/vnd.jupyter.widget-view+json": { "model_id": "67f75d0e635b41a488f77601d930e4d1", "version_major": 2, "version_minor": 0 }, "text/plain": [ "modules.json: 0%| | 0.00/349 [00:00\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTargetJTargetTargetEnglish研究・治験の目的試験等のフェーズ試験の種類...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
32jRCT2031240476NCT06312176NaNホルモン受容体陽性・ヒト上皮成長因子受容体2陰性（HR+/HER2-）の切除不能な局所進行又...HR+/HER2-の切除不能局所進行又は転移性乳癌の患者HR+/HER2-の切除不能局所進行又は転移性乳癌の患者HR+/HER2 unresectable locally advanced or meta...HR+/HER2-の切除不能な局所進行又は転移性乳癌患者を対象にMK-2870の単剤及びペム...3NaN...treatment purpose-Has unresectable locally advanced or metastat...-Has breast cancer amenable to treatment with ...18age old overNo limitBothNaNNaNArm A:MK-2870 Participants receive 4 mg/kg of ...[HR+/HER2 unresectable locally advanced, metas...
112jRCT2031240238NaNNaNネクチン-4発現に関連する進行性悪性腫瘍を有する日本人患者を対象にBT8009の安全性、薬物...進行固形癌進行固形癌Advanced solid tumor malignancies第II/III相試験(NCT06225596)で使用予定のBT8009の用量について、単剤療...1NaN...treatment purpose1. Eastern Cooperative Oncology Group (ECOG) o...1. Current treatment with strong inhibitors or...18age old overNo limitBothNaNNaNIn Part A, (BT8009 monotherapy) participants w...[Advanced solid tum, malignancies]
157jRCT2052240059NaNNaN遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...乳がん乳がんBreast cancerHSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...2NaN...diagnostic purpose1. Histologically confirmed invasive breast ca...1. History of other malignancy within the last...20age old overNo limitFemaleNaNNaNOmitting breast surgery after preoperative che...[Breast cancer]
170jRCT2031240096NCT06380751NaN本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...進行乳癌進行乳癌Advanced Breast CancerTreatment3NaN...treatment purpose- Adult females, pre/peri-menopausal and/or po...- Participants with history of MDS/AML or with...18age old overNo limitBothNaNNaNExperimental: Arm 1: saruparib (AZD5305) plus ...[Advanced Breast Cancer]
209jRCT2031230750NCT06188559NaN治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に，...HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌HER2-positive or HER2-low unresectable or meta...治療2NaN...treatment purpose(1) Male or female, aged >=18 years at the tim...(1) Presence of brain or subdural metastases, ...18age old overNo limitBothNaNNaNGeneric Name:NA Study Treatment in dose optimi...[HER2-positive, HER2-low unresectable, metasta...
215jRCT2031230723NCT06112379NaN未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...乳癌乳癌Breast Cancer未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...3NaN...treatment purpose1. Participant must be >= 18 years at the time...1. As judged by the investigator, any evidence...18age old overNo limitBothNaNNaN- Experimental arm: Dato-DXd plus durvalumab n...[Breast Cancer]
224jRCT2051230196NCT06105632NaNCDK4/6 阻害薬による前治療で進行したホルモン受容体陽性HER2 陰性の進行または転移乳...ホルモン受容体（HR）陽性ヒト上皮増殖因子受容体2（HER2）陰性の進行または転移乳癌ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌HR-positive, HER2-negative Advanced or Metasta...CDK4/6阻害薬による前治療で進行したHR陽性HER2陰性の進行または転移乳癌患者を対象に...3NaN...treatment purpose* Histological confirmation of breast cancer w...* Any medical or psychiatric condition that ma...18age old overNo limitBothNaNNaNArm A (Experimental Arm) PF-07220060 plus Fulv...[HR-positive, HER2-negative Advanced, Metastat...
234jRCT2031230677NCT06206837NaN18歳以上のER陽性／HER2陰性の進行または転移乳癌患者を対象として，経口タンパク質分解誘...エストロゲン受容体陽性／ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌ER+/HER2- advanced or metastatic breast cancer進行乳癌患者を対象として,vepdegestrantとPF-07220060を併用投与したと...1-2NaN...treatment purposeInclusion Criteria: * Histological or cytologi...Exclusion Criteria: * visceral crisis at risk ...18age old overNo limitBothNaNNaNDrug: vepdegestrant Daily oral dosages of vepd...[ER+/HER2- advanced, metastatic breast cancer]
240jRCT2061230102NCT06103864NaNProgrammed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...乳癌乳癌Breast CancerPD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...3NaN...treatment purposeHistologically or cytologically documented loc...As judged by investigator, severe or uncontrol...18age old overNo limitBothNaNNaNArm 1: Dato-DXd + durvalumab Arm 2: Investigat...[Breast Cancer]
307jRCT2061230074NCT05952557NaN根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men; 18 years or more at the time ...- Inoperable locally advanced or metastatic br...18age old overNo limitNaNNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
351jRCT2031230279NCT05862285NaNGENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...癌癌Cancer本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...3NaN...treatment purpose- Eligible for continuing Roche IMP-based ther...- Meet any of the study treatment discontinuat...18age old overNo limitBothNaNNaNIpatasertib: Ipatasertib will be administered ...[Cancer]
392jRCT2031230096NCT05774951NaN根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men, greater than or equal to 18 y...- Inoperable locally advanced or metastatic br...18age old overNo limitBothNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
463jRCT2061220087NCT05629585NaN術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...乳癌乳癌Breast Cancer術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...3NaN...treatment purposeParticipant must be >= 18 years at the time of...Stage IV (metastatic) TNBC. History of prior i...18age old over130age old underBothNaNNaNArm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...[Breast Cancer]
515jRCT2031220276NCT05307705NaNPIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...乳がん乳がんBreast CancerLOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...1NaN...treatment purpose-Have advanced breast cancer or another solid ...-Medical Conditions -Colorectal cancer -Endome...18age old overNo limitBothNaNNaN-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...[Breast Cancer]
555jRCT2031220034NCT04862663NaN局所進行（切除不能）又は転移性のホルモン受容体陽性／ヒト上皮細胞成長因子受容体2 陰性乳癌を...局所進行（切除不能）又は転移性乳癌局所進行(切除不能)又は転移性乳癌Locally Advanced (Inoperable) or Metastatic Br...Treatment3NaN...treatment purposeKey inclusion criteria for both phases: 1. Adu...Key exclusion criteria for both phases: 1. His...18age old over99age old underBothNaNNaNCapivasertib: PO BD 4 days on /3 days off per ...[Locally Advanced (Inoperable), Metastatic Bre...
590jRCT2031210585NCT05123482NaN進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...乳癌、胆道癌、卵巣癌、子宮内膜癌乳癌、胆道癌、卵巣癌、子宮内膜癌Breast Cancer, Biliary Tract Carcinoma, Ovaria...進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究1-2NaN...treatment purpose- Age18 years or more - Relapsed/metastatic so...- Treatment with any of the following: 1. Nitr...18age old overNo limitBothNaNNaNSub-study1 AZD8205 Monotherapy AZD8205 is an a...[Breast Cancer, Biliary Tract Carcinoma, Ovari...
593jRCT2031210560NCT05061823NaN複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...固形癌固形癌Cancer本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...3NaN...treatment purpose- Participants who are currently enrolled in a...- Participants who are pregnant or currently i...18age old overNo limitBothNaNNaNParticipants who are continuing treatment with...[Cancer]
629jRCT2052210099NaNNaN乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...乳がん乳がんBreast cancer本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...2NaN...screeningBreast cancer (including suspected) (1) One of...(1) There is trauma with bleeding on the breas...20age old overNo limitFemaleNaNNaNThe test using IGS-0001 will be performed twic...[Breast cancer]
729jRCT2031200057NaNNaN治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験乳がん乳がんBreast cancerTDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...1NaN...treatment purpose<Disease Characteristics> 1)Patients with inop...1)Patients correspond to either of the followi...20age old overNo limitFemaleNaNBreast cancerFor the target tumor, the dose settled at each...[Breast cancer]
\n", "

19 rows × 40 columns

\n", "" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "32 jRCT2031240476 NCT06312176 NaN \n", "112 jRCT2031240238 NaN NaN \n", "157 jRCT2052240059 NaN NaN \n", "170 jRCT2031240096 NCT06380751 NaN \n", "209 jRCT2031230750 NCT06188559 NaN \n", "215 jRCT2031230723 NCT06112379 NaN \n", "224 jRCT2051230196 NCT06105632 NaN \n", "234 jRCT2031230677 NCT06206837 NaN \n", "240 jRCT2061230102 NCT06103864 NaN \n", "307 jRCT2061230074 NCT05952557 NaN \n", "351 jRCT2031230279 NCT05862285 NaN \n", "392 jRCT2031230096 NCT05774951 NaN \n", "463 jRCT2061220087 NCT05629585 NaN \n", "515 jRCT2031220276 NCT05307705 NaN \n", "555 jRCT2031220034 NCT04862663 NaN \n", "590 jRCT2031210585 NCT05123482 NaN \n", "593 jRCT2031210560 NCT05061823 NaN \n", "629 jRCT2052210099 NaN NaN \n", "729 jRCT2031200057 NaN NaN \n", "\n", " Title \\\n", "32 ホルモン受容体陽性・ヒト上皮成長因子受容体2陰性（HR+/HER2-）の切除不能な局所進行又... \n", "112 ネクチン-4発現に関連する進行性悪性腫瘍を有する日本人患者を対象にBT8009の安全性、薬物... \n", "157 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... \n", "170 本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER... \n", "209 治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に，... \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... \n", "224 CDK4/6 阻害薬による前治療で進行したホルモン受容体陽性HER2 陰性の進行または転移乳... \n", "234 18歳以上のER陽性／HER2陰性の進行または転移乳癌患者を対象として，経口タンパク質分解誘... \n", "240 Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性... \n", "307 根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ... \n", "351 GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に... \n", "392 根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも... \n", "463 術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～... \n", "515 PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... \n", "555 局所進行（切除不能）又は転移性のホルモン受容体陽性／ヒト上皮細胞成長因子受容体2 陰性乳癌を... \n", "590 進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に... \n", "593 複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す... \n", "629 乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... \n", "729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 \n", "\n", " TargetJ \\\n", "32 HR+/HER2-の切除不能局所進行又は転移性乳癌の患者 \n", "112 進行固形癌 \n", "157 乳がん \n", "170 進行乳癌 \n", "209 HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌 \n", "215 乳癌 \n", "224 ホルモン受容体（HR）陽性ヒト上皮増殖因子受容体2（HER2）陰性の進行または転移乳癌 \n", "234 エストロゲン受容体陽性／ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌 \n", "240 乳癌 \n", "307 乳がん、早期乳がん \n", "351 癌 \n", "392 乳がん、早期乳がん \n", "463 乳癌 \n", "515 乳がん \n", "555 局所進行（切除不能）又は転移性乳癌 \n", "590 乳癌、胆道癌、卵巣癌、子宮内膜癌 \n", "593 固形癌 \n", "629 乳がん \n", "729 乳がん \n", "\n", " Target \\\n", "32 HR+/HER2-の切除不能局所進行又は転移性乳癌の患者 \n", "112 進行固形癌 \n", "157 乳がん \n", "170 進行乳癌 \n", "209 HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌 \n", "215 乳癌 \n", "224 ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌 \n", "234 エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌 \n", "240 乳癌 \n", "307 乳がん、早期乳がん \n", "351 癌 \n", "392 乳がん、早期乳がん \n", "463 乳癌 \n", "515 乳がん \n", "555 局所進行(切除不能)又は転移性乳癌 \n", "590 乳癌、胆道癌、卵巣癌、子宮内膜癌 \n", "593 固形癌 \n", "629 乳がん \n", "729 乳がん \n", "\n", " TargetEnglish \\\n", "32 HR+/HER2 unresectable locally advanced or meta... \n", "112 Advanced solid tumor malignancies \n", "157 Breast cancer \n", "170 Advanced Breast Cancer \n", "209 HER2-positive or HER2-low unresectable or meta... \n", "215 Breast Cancer \n", "224 HR-positive, HER2-negative Advanced or Metasta... \n", "234 ER+/HER2- advanced or metastatic breast cancer \n", "240 Breast Cancer \n", "307 Breast Cancer, Early Breast Cancer \n", "351 Cancer \n", "392 Breast Cancer, Early Breast Cancer \n", "463 Breast Cancer \n", "515 Breast Cancer \n", "555 Locally Advanced (Inoperable) or Metastatic Br... \n", "590 Breast Cancer, Biliary Tract Carcinoma, Ovaria... \n", "593 Cancer \n", "629 Breast cancer \n", "729 Breast cancer \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n", "32 HR+/HER2-の切除不能な局所進行又は転移性乳癌患者を対象にMK-2870の単剤及びペム... 3 NaN ... \n", "112 第II/III相試験(NCT06225596)で使用予定のBT8009の用量について、単剤療... 1 NaN ... \n", "157 HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... 2 NaN ... \n", "170 Treatment 3 NaN ... \n", "209 治療 2 NaN ... \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... 3 NaN ... \n", "224 CDK4/6阻害薬による前治療で進行したHR陽性HER2陰性の進行または転移乳癌患者を対象に... 3 NaN ... \n", "234 進行乳癌患者を対象として,vepdegestrantとPF-07220060を併用投与したと... 1-2 NaN ... \n", "240 PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... 3 NaN ... \n", "307 Treatment 3 NaN ... \n", "351 本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療... 3 NaN ... \n", "392 Treatment 3 NaN ... \n", "463 術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... 3 NaN ... \n", "515 LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... 1 NaN ... \n", "555 Treatment 3 NaN ... \n", "590 進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究 1-2 NaN ... \n", "593 本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC... 3 NaN ... \n", "629 本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... 2 NaN ... \n", "729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n", "\n", " purpose Inclusion Criteria \\\n", "32 treatment purpose -Has unresectable locally advanced or metastat... \n", "112 treatment purpose 1. Eastern Cooperative Oncology Group (ECOG) o... \n", "157 diagnostic purpose 1. Histologically confirmed invasive breast ca... \n", "170 treatment purpose - Adult females, pre/peri-menopausal and/or po... \n", "209 treatment purpose (1) Male or female, aged >=18 years at the tim... \n", "215 treatment purpose 1. Participant must be >= 18 years at the time... \n", "224 treatment purpose * Histological confirmation of breast cancer w... \n", "234 treatment purpose Inclusion Criteria: * Histological or cytologi... \n", "240 treatment purpose Histologically or cytologically documented loc... \n", "307 treatment purpose - Women and Men; 18 years or more at the time ... \n", "351 treatment purpose - Eligible for continuing Roche IMP-based ther... \n", "392 treatment purpose - Women and Men, greater than or equal to 18 y... \n", "463 treatment purpose Participant must be >= 18 years at the time of... \n", "515 treatment purpose -Have advanced breast cancer or another solid ... \n", "555 treatment purpose Key inclusion criteria for both phases: 1. Adu... \n", "590 treatment purpose - Age18 years or more - Relapsed/metastatic so... \n", "593 treatment purpose - Participants who are currently enrolled in a... \n", "629 screening Breast cancer (including suspected) (1) One of... \n", "729 treatment purpose 1)Patients with inop... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "32 -Has breast cancer amenable to treatment with ... 18age old over \n", "112 1. Current treatment with strong inhibitors or... 18age old over \n", "157 1. History of other malignancy within the last... 20age old over \n", "170 - Participants with history of MDS/AML or with... 18age old over \n", "209 (1) Presence of brain or subdural metastases, ... 18age old over \n", "215 1. As judged by the investigator, any evidence... 18age old over \n", "224 * Any medical or psychiatric condition that ma... 18age old over \n", "234 Exclusion Criteria: * visceral crisis at risk ... 18age old over \n", "240 As judged by investigator, severe or uncontrol... 18age old over \n", "307 - Inoperable locally advanced or metastatic br... 18age old over \n", "351 - Meet any of the study treatment discontinuat... 18age old over \n", "392 - Inoperable locally advanced or metastatic br... 18age old over \n", "463 Stage IV (metastatic) TNBC. History of prior i... 18age old over \n", "515 -Medical Conditions -Colorectal cancer -Endome... 18age old over \n", "555 Key exclusion criteria for both phases: 1. His... 18age old over \n", "590 - Treatment with any of the following: 1. Nitr... 18age old over \n", "593 - Participants who are pregnant or currently i... 18age old over \n", "629 (1) There is trauma with bleeding on the breas... 20age old over \n", "729 1)Patients correspond to either of the followi... 20age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria Keyword \\\n", "32 No limit Both NaN NaN \n", "112 No limit Both NaN NaN \n", "157 No limit Female NaN NaN \n", "170 No limit Both NaN NaN \n", "209 No limit Both NaN NaN \n", "215 No limit Both NaN NaN \n", "224 No limit Both NaN NaN \n", "234 No limit Both NaN NaN \n", "240 No limit Both NaN NaN \n", "307 No limit NaN NaN NaN \n", "351 No limit Both NaN NaN \n", "392 No limit Both NaN NaN \n", "463 130age old under Both NaN NaN \n", "515 No limit Both NaN NaN \n", "555 99age old under Both NaN NaN \n", "590 No limit Both NaN NaN \n", "593 No limit Both NaN NaN \n", "629 No limit Female NaN NaN \n", "729 No limit Female NaN Breast cancer \n", "\n", " Intervention(s) \\\n", "32 Arm A:MK-2870 Participants receive 4 mg/kg of ... \n", "112 In Part A, (BT8009 monotherapy) participants w... \n", "157 Omitting breast surgery after preoperative che... \n", "170 Experimental: Arm 1: saruparib (AZD5305) plus ... \n", "209 Generic Name:NA Study Treatment in dose optimi... \n", "215 - Experimental arm: Dato-DXd plus durvalumab n... \n", "224 Arm A (Experimental Arm) PF-07220060 plus Fulv... \n", "234 Drug: vepdegestrant Daily oral dosages of vepd... \n", "240 Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... \n", "307 arm A: continue with SoC ET as directed by inv... \n", "351 Ipatasertib: Ipatasertib will be administered ... \n", "392 arm A: continue with SoC ET as directed by inv... \n", "463 Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... \n", "515 -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... \n", "555 Capivasertib: PO BD 4 days on /3 days off per ... \n", "590 Sub-study1 AZD8205 Monotherapy AZD8205 is an a... \n", "593 Participants who are continuing treatment with... \n", "629 The test using IGS-0001 will be performed twic... \n", "729 For the target tumor, the dose settled at each... \n", "\n", " TargetWord \n", "32 [HR+/HER2 unresectable locally advanced, metas... \n", "112 [Advanced solid tum, malignancies] \n", "157 [Breast cancer] \n", "170 [Advanced Breast Cancer] \n", "209 [HER2-positive, HER2-low unresectable, metasta... \n", "215 [Breast Cancer] \n", "224 [HR-positive, HER2-negative Advanced, Metastat... \n", "234 [ER+/HER2- advanced, metastatic breast cancer] \n", "240 [Breast Cancer] \n", "307 [Breast Cancer, Early Breast Cancer] \n", "351 [Cancer] \n", "392 [Breast Cancer, Early Breast Cancer] \n", "463 [Breast Cancer] \n", "515 [Breast Cancer] \n", "555 [Locally Advanced (Inoperable), Metastatic Bre... \n", "590 [Breast Cancer, Biliary Tract Carcinoma, Ovari... \n", "593 [Cancer] \n", "629 [Breast cancer] \n", "729 [Breast cancer] \n", "\n", "[19 rows x 40 columns]" ] }, "execution_count": 53, "metadata": {}, "output_type": "execute_result" } ], "source": [ "# ターゲットリスト全体を処理\n", "matched_indices = []\n", "target_vecs_list = []\n", "cosine_scores_list = []\n", "for idx, target_words in enumerate(basedf['TargetWord']):\n", " # ターゲット内の各単語をベクトル化\n", " target_vecs = model.encode(target_words, convert_to_tensor=True)\n", " # コサイン類似度を計算\n", " cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n", " target_vecs_list.append(target_vecs)\n", " cosine_scores_list.append(cosine_scores)\n", " # 閾値を超えるか確認\n", " if (cosine_scores >= threshold).any(): # いずれかが閾値を超えている場合\n", " matched_indices.append(idx)\n", "\n", "# 抽出\n", "matched_df = basedf.iloc[matched_indices]\n", "matched_df" ] }, { "cell_type": "code", "execution_count": 42, "metadata": {}, "outputs": [], "source": [ "# 全データのターゲット列をベクトル化\n", "target_list = basedf['TargetEnglish'].tolist()\n", "target_vecs = model.encode(target_list, convert_to_tensor=True)\n", "# コサイン類似度を計算\n", "cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()" ] }, { "cell_type": "code", "execution_count": 43, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTargetJTargetTargetEnglish研究・治験の目的試験等のフェーズ試験の種類...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
157jRCT2052240059NaNNaN遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...乳がん乳がんBreast cancerHSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...2NaN...diagnostic purpose1. Histologically confirmed invasive breast ca...1. History of other malignancy within the last...20age old overNo limitFemaleNaNNaNOmitting breast surgery after preoperative che...[Breast cancer]
170jRCT2031240096NCT06380751NaN本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...進行乳癌進行乳癌Advanced Breast CancerTreatment3NaN...treatment purpose- Adult females, pre/peri-menopausal and/or po...- Participants with history of MDS/AML or with...18age old overNo limitBothNaNNaNExperimental: Arm 1: saruparib (AZD5305) plus ...[Advanced Breast Cancer]
215jRCT2031230723NCT06112379NaN未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...乳癌乳癌Breast Cancer未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...3NaN...treatment purpose1. Participant must be >= 18 years at the time...1. As judged by the investigator, any evidence...18age old overNo limitBothNaNNaN- Experimental arm: Dato-DXd plus durvalumab n...[Breast Cancer]
240jRCT2061230102NCT06103864NaNProgrammed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...乳癌乳癌Breast CancerPD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...3NaN...treatment purposeHistologically or cytologically documented loc...As judged by investigator, severe or uncontrol...18age old overNo limitBothNaNNaNArm 1: Dato-DXd + durvalumab Arm 2: Investigat...[Breast Cancer]
307jRCT2061230074NCT05952557NaN根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men; 18 years or more at the time ...- Inoperable locally advanced or metastatic br...18age old overNo limitNaNNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
351jRCT2031230279NCT05862285NaNGENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...癌癌Cancer本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...3NaN...treatment purpose- Eligible for continuing Roche IMP-based ther...- Meet any of the study treatment discontinuat...18age old overNo limitBothNaNNaNIpatasertib: Ipatasertib will be administered ...[Cancer]
392jRCT2031230096NCT05774951NaN根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men, greater than or equal to 18 y...- Inoperable locally advanced or metastatic br...18age old overNo limitBothNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
463jRCT2061220087NCT05629585NaN術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...乳癌乳癌Breast Cancer術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...3NaN...treatment purposeParticipant must be >= 18 years at the time of...Stage IV (metastatic) TNBC. History of prior i...18age old over130age old underBothNaNNaNArm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...[Breast Cancer]
515jRCT2031220276NCT05307705NaNPIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...乳がん乳がんBreast CancerLOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...1NaN...treatment purpose-Have advanced breast cancer or another solid ...-Medical Conditions -Colorectal cancer -Endome...18age old overNo limitBothNaNNaN-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...[Breast Cancer]
593jRCT2031210560NCT05061823NaN複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...固形癌固形癌Cancer本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...3NaN...treatment purpose- Participants who are currently enrolled in a...- Participants who are pregnant or currently i...18age old overNo limitBothNaNNaNParticipants who are continuing treatment with...[Cancer]
629jRCT2052210099NaNNaN乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...乳がん乳がんBreast cancer本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...2NaN...screeningBreast cancer (including suspected) (1) One of...(1) There is trauma with bleeding on the breas...20age old overNo limitFemaleNaNNaNThe test using IGS-0001 will be performed twic...[Breast cancer]
729jRCT2031200057NaNNaN治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験乳がん乳がんBreast cancerTDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...1NaN...treatment purpose<Disease Characteristics> 1)Patients with inop...1)Patients correspond to either of the followi...20age old overNo limitFemaleNaNBreast cancerFor the target tumor, the dose settled at each...[Breast cancer]
\n", "

12 rows × 40 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "157 jRCT2052240059 NaN NaN \n", "170 jRCT2031240096 NCT06380751 NaN \n", "215 jRCT2031230723 NCT06112379 NaN \n", "240 jRCT2061230102 NCT06103864 NaN \n", "307 jRCT2061230074 NCT05952557 NaN \n", "351 jRCT2031230279 NCT05862285 NaN \n", "392 jRCT2031230096 NCT05774951 NaN \n", "463 jRCT2061220087 NCT05629585 NaN \n", "515 jRCT2031220276 NCT05307705 NaN \n", "593 jRCT2031210560 NCT05061823 NaN \n", "629 jRCT2052210099 NaN NaN \n", "729 jRCT2031200057 NaN NaN \n", "\n", " Title TargetJ Target \\\n", "157 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... 乳がん 乳がん \n", "170 本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER... 進行乳癌 進行乳癌 \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... 乳癌 乳癌 \n", "240 Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性... 乳癌 乳癌 \n", "307 根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ... 乳がん、早期乳がん 乳がん、早期乳がん \n", "351 GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に... 癌 癌 \n", "392 根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも... 乳がん、早期乳がん 乳がん、早期乳がん \n", "463 術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～... 乳癌 乳癌 \n", "515 PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... 乳がん 乳がん \n", "593 複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す... 固形癌 固形癌 \n", "629 乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... 乳がん 乳がん \n", "729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 乳がん 乳がん \n", "\n", " TargetEnglish \\\n", "157 Breast cancer \n", "170 Advanced Breast Cancer \n", "215 Breast Cancer \n", "240 Breast Cancer \n", "307 Breast Cancer, Early Breast Cancer \n", "351 Cancer \n", "392 Breast Cancer, Early Breast Cancer \n", "463 Breast Cancer \n", "515 Breast Cancer \n", "593 Cancer \n", "629 Breast cancer \n", "729 Breast cancer \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n", "157 HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... 2 NaN ... \n", "170 Treatment 3 NaN ... \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... 3 NaN ... \n", "240 PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... 3 NaN ... \n", "307 Treatment 3 NaN ... \n", "351 本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療... 3 NaN ... \n", "392 Treatment 3 NaN ... \n", "463 術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... 3 NaN ... \n", "515 LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... 1 NaN ... \n", "593 本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC... 3 NaN ... \n", "629 本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... 2 NaN ... \n", "729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n", "\n", " purpose Inclusion Criteria \\\n", "157 diagnostic purpose 1. Histologically confirmed invasive breast ca... \n", "170 treatment purpose - Adult females, pre/peri-menopausal and/or po... \n", "215 treatment purpose 1. Participant must be >= 18 years at the time... \n", "240 treatment purpose Histologically or cytologically documented loc... \n", "307 treatment purpose - Women and Men; 18 years or more at the time ... \n", "351 treatment purpose - Eligible for continuing Roche IMP-based ther... \n", "392 treatment purpose - Women and Men, greater than or equal to 18 y... \n", "463 treatment purpose Participant must be >= 18 years at the time of... \n", "515 treatment purpose -Have advanced breast cancer or another solid ... \n", "593 treatment purpose - Participants who are currently enrolled in a... \n", "629 screening Breast cancer (including suspected) (1) One of... \n", "729 treatment purpose 1)Patients with inop... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "157 1. History of other malignancy within the last... 20age old over \n", "170 - Participants with history of MDS/AML or with... 18age old over \n", "215 1. As judged by the investigator, any evidence... 18age old over \n", "240 As judged by investigator, severe or uncontrol... 18age old over \n", "307 - Inoperable locally advanced or metastatic br... 18age old over \n", "351 - Meet any of the study treatment discontinuat... 18age old over \n", "392 - Inoperable locally advanced or metastatic br... 18age old over \n", "463 Stage IV (metastatic) TNBC. History of prior i... 18age old over \n", "515 -Medical Conditions -Colorectal cancer -Endome... 18age old over \n", "593 - Participants who are pregnant or currently i... 18age old over \n", "629 (1) There is trauma with bleeding on the breas... 20age old over \n", "729 1)Patients correspond to either of the followi... 20age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria Keyword \\\n", "157 No limit Female NaN NaN \n", "170 No limit Both NaN NaN \n", "215 No limit Both NaN NaN \n", "240 No limit Both NaN NaN \n", "307 No limit NaN NaN NaN \n", "351 No limit Both NaN NaN \n", "392 No limit Both NaN NaN \n", "463 130age old under Both NaN NaN \n", "515 No limit Both NaN NaN \n", "593 No limit Both NaN NaN \n", "629 No limit Female NaN NaN \n", "729 No limit Female NaN Breast cancer \n", "\n", " Intervention(s) \\\n", "157 Omitting breast surgery after preoperative che... \n", "170 Experimental: Arm 1: saruparib (AZD5305) plus ... \n", "215 - Experimental arm: Dato-DXd plus durvalumab n... \n", "240 Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... \n", "307 arm A: continue with SoC ET as directed by inv... \n", "351 Ipatasertib: Ipatasertib will be administered ... \n", "392 arm A: continue with SoC ET as directed by inv... \n", "463 Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... \n", "515 -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... \n", "593 Participants who are continuing treatment with... \n", "629 The test using IGS-0001 will be performed twic... \n", "729 For the target tumor, the dose settled at each... \n", "\n", " TargetWord \n", "157 [Breast cancer] \n", "170 [Advanced Breast Cancer] \n", "215 [Breast Cancer] \n", "240 [Breast Cancer] \n", "307 [Breast Cancer, Early Breast Cancer] \n", "351 [Cancer] \n", "392 [Breast Cancer, Early Breast Cancer] \n", "463 [Breast Cancer] \n", "515 [Breast Cancer] \n", "593 [Cancer] \n", "629 [Breast cancer] \n", "729 [Breast cancer] \n", "\n", "[12 rows x 40 columns]" ] }, "execution_count": 43, "metadata": {}, "output_type": "execute_result" } ], "source": [ "matched_indices_d = (cosine_scores >= threshold).nonzero().tolist()\n", "# 入れ子リストをフラットなリストに変換\n", "flat_indices_d = [idx[0] for idx in matched_indices_d]\n", "\n", "# 抽出\n", "matched_df_d = basedf.iloc[flat_indices_d]\n", "matched_df_d\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] }, { "cell_type": "markdown", "metadata": {}, "source": [ "\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] } ], "metadata": { "kernelspec": { "display_name": "gradio", "language": "python", "name": "python3" }, "language_info": { "codemirror_mode": { "name": "ipython", "version": 3 }, "file_extension": ".py", "mimetype": "text/x-python", "name": "python", "nbconvert_exporter": "python", "pygments_lexer": "ipython3", "version": "3.12.3" } }, "nbformat": 4, "nbformat_minor": 2 }